ORM Act

This bill directs the Secretary of Labor to issue a workplace safety standard requiring employers to keep opioid overdose reversal drugs on site and to create training plans for responding to drug overdoses. It also expands the Comprehensive Opioid Abuse Grant Program to include training and resources for carrying and administering such drugs, and allows preferential grant consideration for states with certain liability protections.

Sec. 2, Opioid overdose reversal drug standard: Within one year, the Secretary of Labor must issue an interim final standard requiring all employers to keep an FDA-authorized opioid overdose reversal drug or device on site, with the number of doses based on employee count, occupation type, and potential use assessment. The standard must include training guidelines on identifying overdose signs and administering the drug. The Secretary may prioritize technical assistance for up to one year. The interim standard takes effect within 30 days and has the same legal effect as an OSHA standard. If not issued within one year, the bill's provisions take effect until superseded. Within two years, the Secretary must issue a final standard that includes at least the interim requirements.

Sec. 3, Expansion of the Comprehensive Opioid Abuse Grant Program: The bill adds a new allowable use for grants: developing programs that train local businesses, individuals, or community entities likely to encounter people with substance use disorders but not eligible for other federal grants, and providing resources for them to acquire, carry, and administer FDA-authorized opioid overdose reversal drugs. It also allows the Attorney General to give preferential consideration to grant applications from states that have laws exempting from criminal and civil liability individuals who, after training, carry or administer such drugs in good faith.